• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

坦索罗辛预防女性盆底重建术后尿潴留。

Tamsulosin to Prevent Postoperative Urinary Retention After Female Pelvic Reconstructive Surgery.

出版信息

Female Pelvic Med Reconstr Surg. 2020 Nov;26(11):682-687. doi: 10.1097/SPV.0000000000000650.

DOI:10.1097/SPV.0000000000000650
PMID:30418263
Abstract

OBJECTIVE

This study aimed to determine the effect of tamsulosin on postoperative urinary retention in female patients after pelvic reconstructive surgery.

METHODS

Data were obtained from a retrospective, matched cohort of female patients who were admitted after pelvic reconstructive surgery at a single academic institution. Patients who received tamsulosin were compared with those who did not at a 1:4 ratio, matched by surgical procedure. Patients were excluded if they were discharged on the day of surgery or if an intraoperative complication necessitated prolonged postoperative bladder drainage. Information on demographics, preoperative diagnoses, prolapse stage, preoperative voiding dysfunction, urodynamic findings, intraoperative details, postoperative complications, and voiding outcomes up to 6 weeks after surgery was gathered. The primary outcome was postoperative urinary retention, defined by failure of an active voiding trial.

RESULTS

Patients underwent surgery between January 2016 and March 2018. We identified 35 patients who received tamsulosin and matched to 140 controls. Patients in the tamsulosin group were younger; groups were otherwise similar. Patients who received tamsulosin after surgery were less likely to develop postoperative urinary retention (2.9% vs 24.3%, P = 0.004). After controlling for confounders, multivariable logistic regression identified tamsulosin use as the only independent predictor of postoperative urinary retention with a significant protective effect (odds ratio, 0.09; 95% confidence interval, 0.01-0.67; P = 0.03).

CONCLUSIONS

Prophylactic tamsulosin use may be effective in preventing postoperative urinary retention in female patients undergoing pelvic reconstructive surgery.

摘要

目的

本研究旨在确定坦索罗辛对女性盆腔重建术后患者术后尿潴留的影响。

方法

资料来源于单家学术机构收治的女性盆腔重建术后患者的回顾性、匹配队列研究。以 1:4 的比例,按手术程序将接受坦索罗辛治疗的患者与未接受坦索罗辛治疗的患者进行匹配。如果患者在手术当天出院,或术中并发症需要延长术后膀胱引流,则排除患者。收集了人口统计学、术前诊断、脱垂分期、术前排尿功能障碍、尿动力学检查结果、手术细节、术后并发症以及术后 6 周内排尿结果等信息。主要结局是术后尿潴留,定义为主动排尿试验失败。

结果

患者于 2016 年 1 月至 2018 年 3 月期间接受手术。共识别出 35 例接受坦索罗辛治疗的患者,并与 140 例对照患者相匹配。坦索罗辛组患者更年轻,两组在其他方面相似。接受坦索罗辛治疗的患者发生术后尿潴留的可能性较低(2.9% vs. 24.3%,P=0.004)。在控制混杂因素后,多变量逻辑回归发现坦索罗辛的使用是术后尿潴留的唯一独立预测因素,具有显著的保护作用(比值比,0.09;95%置信区间,0.01-0.67;P=0.03)。

结论

在接受盆腔重建手术的女性患者中,预防性使用坦索罗辛可能有效预防术后尿潴留。

相似文献

1
Tamsulosin to Prevent Postoperative Urinary Retention After Female Pelvic Reconstructive Surgery.坦索罗辛预防女性盆底重建术后尿潴留。
Female Pelvic Med Reconstr Surg. 2020 Nov;26(11):682-687. doi: 10.1097/SPV.0000000000000650.
2
Tamsulosin vs placebo to prevent postoperative urinary retention following female pelvic reconstructive surgery: a multicenter randomized controlled trial.坦索罗辛对比安慰剂预防女性盆底重建术后尿潴留:一项多中心随机对照试验。
Am J Obstet Gynecol. 2021 Sep;225(3):274.e1-274.e11. doi: 10.1016/j.ajog.2021.04.236. Epub 2021 Apr 21.
3
Optimal timing of a second postoperative voiding trial in women with incomplete bladder emptying after vaginal reconstructive surgery: a randomized trial.阴道重建术后膀胱排空不全会女性行二次排尿试验的最佳时机:一项随机试验。
Am J Obstet Gynecol. 2020 Aug;223(2):260.e1-260.e9. doi: 10.1016/j.ajog.2020.06.001. Epub 2020 Jun 3.
4
Predictors of delayed postoperative urinary retention after female pelvic reconstructive surgery.女性盆底重建术后尿潴留延迟的预测因素。
Int Urogynecol J. 2021 Mar;32(3):603-608. doi: 10.1007/s00192-020-04372-8. Epub 2020 Jun 12.
5
Perioperative use of tamsulosin significantly decreases rates of urinary retention in men undergoing pelvic surgery.坦索罗辛在围手术期的使用显著降低了接受盆腔手术男性的尿潴留发生率。
Int J Colorectal Dis. 2015 Sep;30(9):1223-8. doi: 10.1007/s00384-015-2294-7. Epub 2015 Jun 23.
6
Predictors of early postoperative voiding dysfunction and other complications following a midurethral sling.经阴道无张力尿道中段悬吊带术后早期排尿功能障碍及其他并发症的预测因素
Am J Obstet Gynecol. 2016 Nov;215(5):656.e1-656.e6. doi: 10.1016/j.ajog.2016.06.010. Epub 2016 Jun 16.
7
Effectiveness of tamsulosin in prevention of post-operative urinary retention: a randomized double-blind placebo-controlled study.坦索罗辛预防术后尿潴留的有效性:一项随机双盲安慰剂对照研究。
Int Braz J Urol. 2014 Jan-Feb;40(1):30-6. doi: 10.1590/S1677-5538.IBJU.2014.01.05.
8
The AAHKS Clinical Research Award: Prophylactic Tamsulosin Does Not Reduce the Risk of Urinary Retention Following Lower Extremity Arthroplasty: A Double-Blinded Randomized Controlled Trial.AAHKS 临床研究奖:预防性坦索罗辛不能降低下肢关节置换术后尿潴留的风险:一项双盲随机对照试验。
J Arthroplasty. 2019 Jul;34(7S):S17-S23. doi: 10.1016/j.arth.2019.03.039. Epub 2019 Mar 20.
9
Preventive effects of tamsulosin for postoperative urinary retention after lower limb arthroplasty: A randomized controlled study.坦索罗辛预防下肢关节置换术后尿潴留的效果:一项随机对照研究。
Investig Clin Urol. 2021 Sep;62(5):569-576. doi: 10.4111/icu.20200523. Epub 2021 Aug 3.
10
Prophylactic effects of alpha-blockers, Tamsulosin and Alfuzosin, on postoperative urinary retention in male patients undergoing urologic surgery under spinal anaesthesia.α受体阻滞剂坦索罗辛和阿夫唑嗪对接受脊髓麻醉下泌尿外科手术的男性患者术后尿潴留的预防作用。
Int Braz J Urol. 2016 May-Jun;42(3):578-84. doi: 10.1590/S1677-5538.IBJU.2015.0256.

引用本文的文献

1
Effect of Preoperative Tamsulosin on Postoperative Urinary Retention Prevention After Sling Placement: A Randomized Controlled Trial.术前坦索罗辛对吊带置入术后预防尿潴留的效果:一项随机对照试验
Int Urogynecol J. 2025 Apr 12. doi: 10.1007/s00192-025-06120-2.
2
Effectiveness of Electroacupuncture for Managing Urinary Retention Post Lumbar Spine Surgery: a retrospective single-cohort study.电针治疗腰椎手术后尿潴留的有效性:一项回顾性单队列研究。
J Pharmacopuncture. 2024 Jun 30;27(2):123-130. doi: 10.3831/KPI.2024.27.2.123.